Management of crescentic glomerulonephritis: What are the recent advances?

Contributions to Nephrology

Volumn 181, Issue , 2013, Pages 229-239

  Li, Xiao ^a   Chen, Nan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLOMERULAR BASEMENT MEMBRANE ANTIBODY; AUTOANTIBODY; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANCA ASSOCIATED VASCULITIS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; DRUG ANTAGONISM; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; GLOMERULONEPHRITIS; HUMANS; MYCOPHENOLIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84958676350     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000348479     Document Type: Article

References (33)

1. Couser WG: Rapidly progressive glomerulo-nephritis: classification, pathogeneticl mechanisms, and therapy. Am J Kidney Dis 1988; 11:449-464.
2. Jennette JC, Thomas DB: Crescentic glomer-ulonephritis. Nephrol Dial Transplant 2001; 16(suppl 6):80-82.
3. Tam FW: Current pharmacotherapy for the treatment of crescentic glomerulonephritis. Expert Opin Investig Drugs 2006; 15:1353-1369. (Pubitemid 44615285)
4. Bolton WK: Goodpasture's syndrome. Kidney Int 1996; 50:1753-1766. (Pubitemid 26364285)
5. KDIGO clinical practice guideline for glo-merulonephritis. Kidney Int Suppl 2012; 2:200-242.
6. Levy JB, Turner AN, Rees AJ, Pusey CD: Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppres-sion. Ann Intern Med 2001; 134:1033-1042. (Pubitemid 32488657)
7. Cui Z, Zhao J, Jia XY, Zhu SN, Jin QZ, Cheng XY, Zhao MH: Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Medicine (Baltimore) 2011; 90:303-311.
8. Li FK, Tse KC, Lam MF, Yip TP, Lui SL, Chan GS, Chan KW, Chan EY, Choy BY, Lo WK, Chan TM, Lai KN: Incidence and outcome of antiglomerular basement membrane disease in Chinese. Nephrology (Carlton) 2004; 9:100-104. (Pubitemid 38530453)
9. Hirayama K, Yamagata K, Kobayashi M, Koyama A: Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulone-phritis survey in Japan. Clin Exp Nephrol 2008; 12:339-347.
10. Chan AL, Louie S, Leslie KO, Juarez MM, Albertson TE: Cutting edge issues in Good-pasture's disease. Clin Rev Allergy Immunol 2011; 41:151-162.
11. Bosch X, Mirapeix E, Font J, Borrellas X, Ro-dríguez R, López-Soto A, Ingelmo M, Revert L: Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloper-oxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 1991; 36:107-113.
12. Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD: Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535-1540. (Pubitemid 39298387)
13. Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, Ren H, Pan X, Chen X, Zhang W, Li X, Shi H, Li Y, Gharavi AG, Chen N: Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One 2012; 7:e38904.
14. Barratt J, Feehally J: Treatment of IgA ne-phropathy. Kidney Int 2006; 69:1934-1938.
15. Pankhurst T, Lepenies J, Nightingale P, Howie AJ, Adu D, Harper L: Vasculitic IgA ne-phropathy: prognosis and outcome. Nephron Clin Pract 2009; 112:c16-c24.
16. El-Husseini AA, Sheashaa HA, Sabry AA, Moustafa FE, Sobh MA: Acute postinfectious crescentic glomerulonephritis: clinicopatho-logic presentation and risk factors. Int Urol Nephrol 2005; 37:603-609. (Pubitemid 41762526)
17. Zaffanello M, Cataldi L, Franchini M, Fanos V: Evidence-based treatment limitations prevent any therapeutic recommendation for acute poststreptococcal glomerulonephritis in children. Med Sci Monit 2010; 16:RA79-RA84.
18. Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME: Lupus nephritis: a critical review. Autoimmun Rev 2012; 12:174-194.
19. Li X, Ren H, Zhang QY, Zhang W, Wu XJ, Xu YW, Shen PY, Chen N: Mycophenolate mofetil, tacrolimus and intravenous cyclo-phosphamide for the induction treatment of active lupus nephritis. Nephrol Dial Transplant 2012; 27:1467-1472.
20. Malho A, Santos V, Cabrita A, Silva AP, Pinto I, Bernardo I, Neves PL: Severe relapsing Goodpasture's disease successfully treated with mycophenolate mofetil. Int J Nephrol 2012; 2010:383548.
21. García-Cantón C, Toledo A, Palomar R, Fernandez F, Lopez J, Moreno A, Esparza N, Su-ria S, Rossique P, Diaz JM, Checa D: Good-pasture's syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant 2000; 15:920-922. (Pubitemid 30312025)
22. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF: Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65:1842-1849. (Pubitemid 38591034)
23. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G: Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: a doubleblind randomized controlled trial. Nephrol Dial Transplant 2005; 20:2139-2145. (Pubitemid 41510089)
24. Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68:802-812. (Pubitemid 43323137)
25. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L: Mycophenolate mofetil versus cyclophospha-mide for inducing remission of ANCA vascu-litis with moderate renal involvement. Nephrol Dial Transplant 2008; 23:1307-1312. (Pubitemid 351767500)
26. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weit-zenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group: Rituximab versus cyclophosphamide for AN-CA-associated vasculitis. N Engl J Med 2010; 363:221-232.
27. Arzoo K, Sadeghi S, Liebman HA: Treatment of refractory antibody-mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61: 922-924.
28. Wiesik-Szewczyk E, Olesinska M: B-cell targeted therapy in systemic lupus erythemato-sus: potential of rituximab. Biologics 2012; 6: 347-354.
29. Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005; 67:1812-1820. (Pubitemid 40577716)
30. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C, Pusey C, Jayne D: Prospective study of TNF-α blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721. (Pubitemid 38294802)
31. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulo-matosis. N Engl J Med 2005; 352:351-361.
32. Chen N, Zhang J, Yu HJ, Zhang W, Chen YX, Wang WM: Computer-aided drug design of a potential and selective small peptide inhibiting interaction of FcγIIa and ANCA. Clin Exp Immunol 2011; 164(suppl 1):74-74.
33. Iyoda M, Shibata T, Kawaguchi M, Yamaoka T, Akizawa T: Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glo-merulonephritis. Kidney Int 2009; 75:1060-1070.